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A B S T R A C TObjective: This study aimed to explore the driving factors of the
increasing anti-infective drug expenditures in Tianjin, China, and to
provide evidence-based suggestions for policymakers. Methods: Data
were extracted from inpatient records in Urban Employee Basic
Medical Insurance data of Tianjin, China, from 2003 January to
December 2007. Expenditure increase for a basket of 63 constantly
used anti-infective drugs was decomposed into three broad cate-
gories: price effects, quantity effects, and therapeutic choices.
Furthermore, the injection anti-infective drug expenditures from
2006 to 2007 were decomposed into six determinants. Results: From
2003 January to December 2007, the expenditure for a fixed basket of
drugs increased by 9%. The driving factors were therapeutic choices
and quantity effects; each increased 48% and 10%, respectively. Thesee front matter & 2013 Published by Elsevier Inc
(ISPOR).
.1016/j.vhri.2013.01.002
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ondence to: Jing Wu, Building 24, Room A506, Weijrelative price decreased by 33% during the study period. After
adding new drugs to the formulary in 2005, the rate of increase in
drug expenditure was 28% from 2006 to 2007; the driving factors
were still therapeutic choice (16.8%) and quantity effects (14.9%).
Conclusions: Therapeutic choice transferring from cheap drugs to
expensive ones, rather than the price, was the main driving factor for
increasing expenditures. Policymakers need to pay more attention
to rationalize physicians’ prescribing behavior to control the
expenditure.
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Over the past decades, high pharmaceutical expenditure and its
continuous growth caught the attention of policymakers around
the world. The World Health Organization reported that pharma-
ceutical expenditure accounted for 7% to 20% of total health
expenditure in developed countries, while it accounted for 24% to
66% in developing countries [1]. In China, pharmaceutical expen-
diture for inpatients and outpatients as a share of total health
expenditure reached 44% and 50.9% in 2009, respectively. In
terms of per-capita pharmaceutical expenditure, it increased at
an average rate of 7% per year from 2000 to 2009 [2]. In response,
for Chinese policymakers, controlling pharmaceutical expendi-
ture is one of the most important components of controlling total
health expenditure.
In China, there are more than 50,000 pharmaceutical products
on the market produced by local, foreign, and joint venture
manufacturers [3]. Policy efforts to contain health expenditure
in China have been focused on controlling the price of pharma-
ceuticals, including maximum retail prices (or price capping),
compelling price reduction, and bidding and group procurement.
The Urban Employee Basic Medical Insurance (UEBMI) reimbur-
sement drug list covers about 20% of the total products on the
market and 60% of the marketing sales, which was the mostusually used drugs in China [3]. The maximum retail prices (price
cap) of these drugs were settled by the National Development and
Reform Commission. Furthermore, the National Development
and Reform Commission has implemented compelling price
reduction more than 24 times since 1997, involving almost all
the drugs under the UEBMI reimbursement drug list. Pharma-
ceutical price was also affected by pharmaceutical bidding and
group procurement policies, which were introduced in medical
institutions in 1990s in China and led by local government as a
major effort to regulate hospital drug procurement.
It has been reported, however, that the decrease in drug price
had a very limited effect on pharmaceutical expenditure control
[4–6]. In fact, while the pharmaceutical price index (single
number that shows the extent of price change over a period for
a basket of drugs) decreased by 10.8% from 2000 to 2009, the
pharmaceutical expenditure index for inpatients and outpatients
increased by 84.2% and 61.4%, respectively [2]. Thus, the driving
factors of increasing pharmaceutical expenditure are still un-
known in China.
To fill this gap, this article aimed to identify major driving
forces of the increasing anti-infective drug expenditure in terms
of price, quantity, and therapeutic choice. The rest of the article is
organized as follows. The second section describes the concep-
tual frameworks, methods, and data. The third section presents. on behalf of International Society for Pharmacoeconomics and
conflicts of interest with regard to the content of this article.
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discussion.Conceptual Frameworks
Relationships between Price, Quantity, and Therapeutic
Choice
The changes in pharmaceutical expenditure can be influenced by
three major factors: price effects, quantity effects, and therapeu-
tic choices (or residual effects) [7–10]. The following formula
presents the mathematic relationships between the pharmaceu-
tical expenditure and these three factors by using a nonstochas-
tic, index-theoretical [11]:
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where Q0 is the quantity of drugs in the basic period, Q1 is the
quantity of drugs in the current period, P0 is the price of each
defined daily dose (DDD) in the basic period, and P1 is the price of
each DDD in the current period.
In Eq. 1,
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are the residual
effects. Price effects, which were estimated by using the Las-
peyres price index (taking the drug quantity at the basic period as
weight), reflect the price changes of a basket of drugs within a
certain period. Quantity effects relate to the quantity changes of
drug therapy for different drugs in different periods. The residual
effect is obtained by comparing the daily drug price in different
periods by taking the drug quantity of basic and new periods as a
weight, a factor reflecting the difference between the actual
pharmaceutical expenditure increase and the multiplied value
of the price index (PI) and the quantity index.
The residual effect is influenced by the behaviors of physi-
cians, which represents the pharmaceutical expenditure changes
because of changes in treatment patterns, reflecting the transfer
from lower (higher) price drugs to higher (lower) price drugs over
time [12]. A residual effect of greater than one indicates that the
treatment patterns transfer from less expensive drugs to expen-
sive ones, and vice versa [8,13,14]. There are two possibilities with
the residual effect when it does not equal one. First, consumption
for a drug is partly or totally replaced by another drug while the
price and the total quantity of the two drugs are constant. Such a
replacement does not result in any change in either the PI or the
quantity index. Second, the residual effect can be affected by
changes in drug quantity if the quantity changes are not con-
sistent with the existing market shares of the drugs. To summar-
ize, the residual effect reflects changes in pharmaceutical
expenditure resulting from switches from one drug to another
or from changes in the total quantity of drugs consumed.
Decomposition of Price, Quantity, and Therapeutic Choices to
Six Potential Determinants
The three broad categories of price effects, quantity effects, and
therapeutic choices can be further decomposed into sixInpatient
admissions 
Inpatient size 
of prescription 
Price
change
Change in 
generics
Quantity
Effects 
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Fig. 1 – Six determinants of per-capitdeterminants, as shown in Fig. 1. Computation of the six
determinants is done by using data aggregated to different levels
of the therapeutic classification system hierarchy. For each of the
six determinants, the basic indices take the form of Fisher’s Ideal
index, which is the geometric mean of Paasche and Laspeyres
indices [15,16].
Price Effects
Price effects include changes in the price charged for every anti-
infective product and changes in the average unit cost of multi-
source anti-infective drugs stemming from generic substitution,
which are represented by the PI and the generics index. PI is
simply changes in prices charged for all the existing anti-
infective products identified by ingredient, dosage, form, and
manufacture (the product level) (Eq. 2). The generics index is the
changes in cost of treatment by substitutions for multisource
alternatives without changing the type of drug, which is mea-
sured by an expenditure-weighted average of changes per unit of
multisource drugs (the drug level) (Eq. 3). The generics index
reflects the impact of substitutions toward lower (or higher) cost
alternatives for multisource drugs. The ratio of a PI at the drug
level (higher level) over an index at the product level (lower level)
of the hierarchy is equal to the cost impact of changing market
shares within the higher level categories.
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where CPU and QPU are expenditure and quantity defined by
ingredient, dosage, form, and manufacture (the product level).
CDU and QDU are expenditure and quantity defined by ingredient,
dosage, and form (the drug level). The current period is repre-
sented by 1, and the base period is presented by 0.
Quantity Effects
Quantity effects include the changes in the number of inpatient
admissions (IA) and the size of anti-infective drug utilization per
inpatient admission. IA are measured by using an expenditure-
weighted average of changes in the number of inpatients using
anti-infective drugs (Eq. 4). Expenditure-weighted admission
number ensures that costly drugs increase the measure of
number more than a similar increase in low-cost drugs. ‘‘Size of
drug utilization (DS)’’ is the changes in the average number of
anti-infective drug units per IA, which is measured by an
expenditure-weighted average of changes in the number of drug
units per admission, in terms of active ingredient, dosage, and
form (the drug level) (Eq. 5).
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Table 1 – Inpatients characteristics in the UEBMI
system from 2003 to 2007 in Tianjin, China.
2003 2004 2005 2006 2007
Patients (K) 86 116 135 148 162
Average age (y) 58.5 59.6 60.6 60.7 61
Males (%) 53.8 51.3 51.9 52.6 52.0
Admissions (K) 127 180 229 257 278
UEBMI, Urban Employee Basic Medical Insurance.
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infective drugs. CDR and QDR are expenditure and quantity
defined by active ingredient, dosage, and form per inpatient
admission.
Therapeutic Choices
Therapeutic choices influence pharmaceutical expenditure
through prescribing different types of anti-infective drugs. These
choices include changes in the mix of therapeutic categories and
changes in the drugs selected within therapeutic categories,
which are presented by therapeutic mix (TM) and drug mix
(DM), respectively. First, TM is measured by expenditure-
weighted average change in expenditures per admission among
different therapeutic treatment categories (Eq. 6). For example, if
relatively high-cost cephalosporin captures a growing share of
treatment instead of penicillin, this is reflected in increasing cost
of the TM for anti-infective drugs. DM is the change in product
types within therapeutic categories according to market share
changes (Eq. 7). For example, an increase in the market share of
cefepime leads to a decrease in the market share of the relatively
low-cephradine, which is reflected in a reduction in the DM
effects.
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where CNR and QNR are aggregate expenditure and quantity
defined by therapeutic categories per inpatient admission; for
example, there are 19 categories within anti-infective drugs.
Data and Methods
The sample of this study was extracted from UEBMI claim data of
Tianjin city, which covered all employees in the urban area of
Tianjin city. The UEBMI system is one of three basic medical
insurance systems in China established in 1998, and its partici-
pation is planned to be mandatory to all employees in both public
and private companies, including government officials and self-
employed persons. This system uses a cost-sharing structure in
which employers (6% of total wages) and employees (2% of their
wage/salary) share the costs of health care. Local governments
are then responsible for the management of the fund. By 2007,
the UEBMI system covered most of the urban employees in
Tianjin city; the beneficiaries covered 34.5% of the registered
residences in Tianjin city [17].
Anti-infective therapeutic categories were selected in the
analysis, which were defined according to the UEBMI Formulary
Classification System. In the formulary, anti-infective drugs have
the following three subcategories: antibiotics (e.g., azithromycin),
antifungals (e.g., itraconazole), and antivirals (e.g., ganciclovir).
The three subcategories can be divided into 19 therapeutic
subclasses, which contain 115 kinds of anti-infective drugs
(calculated by generic name), varying from 73 to 101 in different
years. During the analysis, we assumed drugs with the same
generic name, dosage form, dose, and manufacturer as one
product, and there were 661 products in the sample. The data
used in this study represent the actual retail price charged to the
patients.
We used data of anti-infective drugs utilization from January
2003 to December 2007, and the data were randomly sampled as
10% of the whole data set. We used only inpatient data because
outpatient data were not digitalized from 2003 to 2007. The
injections and oral drugs were selected to be used in the analysis
because they covered most of the utilization and ensuredaccuracy and consistency in the measurement of unit quantity.
Injections include subcutaneous injection, intramuscular injec-
tion, and intravenous injection, while oral drugs include both
solid (such as pill, tablet, capsule, timed-release tablet) and liquid
(such as solution, softgel, suspension, and emulsion) forms.
We used a basket of 63 constantly used drugs during 5 years in
three determinants analysis. In six determinants, only 100 con-
stantly used injections were used to ensure high data quality and
accuracy of results; expenditure on these took up more than 96%
of the total expenditure of anti-infective drugs. Another reason to
choose injections was that drug manufacturers’ information was
imperfect during 2003 to 2005, which is necessary in six deter-
minants analysis.
In the study, the quantity was calculated by the number of
DDDs, that is, DDDs ¼ annual drug quantity consumed/DDD. It is
a quantity unit based on the audit drug DDD recommended by
the World Health Organization. As a corresponding part, the drug
price was calculated by DDD consumed (DDDc), that is, DDDc ¼
annual drug revenue/DDDs. All the data for price and expendi-
ture were standardized to year 2003 Chinese currency (CNY)
using the Consumer Price Index.Results
Table 1 lists the inpatient population characteristics in the UEBMI
system from 2003 to 2007. The number of inpatients increased
from 86,000 in 2003 to 162,000 in 2007, which represented 127,000
IA in 2003 and 278,000 admissions in 2007. The average age was
61 years, and 52% were males in 2007.
Three Determinants of Drug Expenditure
The total expenditure of 63 constantly consumed anti-infective
drugs increased by 8% from 10.7 million CNY in 2003 to 11.6
million CNY in 2007. During 2003 to 2005, these drugs’ expendi-
tures grew at a rate of more than 30%. But, in 2006, the
expenditure decreased by 7% compared with 2003 and there
was a slight increase of 9% in 2007. The fact behind the decreas-
ing expenditures of these 63 constantly consumed drugs in 2006
is that the UEBMI formulary was revised in 2004 by adding drugs,
and the new formulary was implemented in 2005. The change in
the formulary induced the transfer of old products to newly
added products, resulting in the basket of constantly consumed
drug expenditure index decreasing after the transition period
of 2005.
The contribution of price effects, quantity effects, and ther-
apeutic choices to drugs expenditures is shown in Table 2. The
annual quantity growth (DDDs) of 63 constantly consumed anti-
infective drugs during the 5 years was 10%, among which the
growth was 27.5% during 2003 to 2005. The price level (DDDc)
kept decreasing during the 5 years, and it had a 33% decrease in
2007 based on 2003. In contrast with the PI and the quantity
index, the therapeutic choice index showed a significant growth
and attained 48% increase in 2007 than in 2003. The results of
Table 2 – Three determinants indices of anti-infective pharmaceutical expenditure from 2003 to 2007.
Drug category Year Expenditure index Decomposition of pharmaceutical expenditure
Quantity Price Therapeutic choice
Anti-infective drug 2004 1.34 1.26 0.94 1.13
2005 1.33 1.29 0.81 1.27
2006 0.93 1.07 0.62 1.40
2007 1.09 1.10 0.67 1.48
Note. Basic period is 2003.
F
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from cheap products to expensive ones.
Three Determinants of Injections and Oral Drugs Expenditure
To show details among different preparations, injections and oral
drugs’ expenditures were separately decomposed (Figs. 2 and 3).
The total expenditure of injections had the same trend as that of
oral forms, both of which had a significant decrease in 2006, and
then increase in 2007.
Although the trend of expenditure indices was similar among
injections and oral drugs, the driving factors were different. The
quantity index of oral forms decreased from 2003 (index ¼ 1) to
2007 (index ¼ .94). The quantity of injections, however, increased
during the same time (index ¼ 1.22 in 2007). The therapeutic
choice index for oral forms increased by 71% in 5 years, while
injections increased only by 35%. Therefore, the increase in the
expenditure of injections was due to combined effects of the
quantity and therapeutic choice, but for oral forms, only the
therapeutic choice was the main driver.
Six Determinants of Injections Expenditure
The expenditures of anti-infective injections increased from 16.5
million to 20.9 million CNY from 2006 to 2007. This rate of increase
(26.2%) was more than two times of the gross domestic product
increase rate in China, which was 11.4% in the same period [18].
The result of decomposition showed that therapeutic effects
were the most important driving factor of pharmaceutical
expenditures increase (16.8%) (Table 3). Drug substitutions, dif-
ferent generics substitutions within certain anti-infective cate-
gory, had the fastest growth among therapeutic subfactors, with
a contribution of 8.9% for the increase in pharmaceutical expen-
ditures. Therapeutic substitutions, substitutions among the dif-
ferent anti-infective category, had a 7.3% contribution. Second,
quantity effects increased by 14.9% within only 1 year because of
the combined effect of the annual IA (7.0%) and the amount ofig. 2 – Three determinants indices analysis for anti-
nfective injections from 2003 to 2007.
F
iprescription drugs consumed per admission (7.4%). Price effects,
however, had a negative impact on the pharmaceutical expendi-
ture by 6%. The subfactors on price effects were conflicting. The
drug price decreased expenditures by 7.0%, and generic substitu-
tions increased expenditures by 1.1%. The positive effect of
generic substitutions meant that more and more cheap generics
were replaced by expensive alternatives.Conclusions and Discussion
We explored the effect of potential influential factors on the
changes in anti-infective expenditures during 2003 to 2007 in
Tianjin, China. We found that therapeutic choices and quantity
effects were the two most important reasons for pharmaceutical
expenditure increasing. Price, however, had a negative influence
on the increasing pharmaceutical expenditure. Generic substitu-
tion had a positive effect on increasing pharmaceutical expendi-
tures. The driving factors were different among injections and
oral drugs. We conclude that therapeutic choice transferring from
cheap drugs to expensive ones, rather than the price, was the
main driving factor for increasing expenditures.
Our results showed that anti-infective drug price was decreas-
ing during 2003 to 2007, which was in accordance with the drug
price statistics from the Ministry of Health of China [2]. The main
reason for the decreasing price was that China National Devel-
opment and Reform Commission had lowered the drug prices
more than 24 times since 1997 [19], which involved 2425 different
drugs, including most anti-infective drugs. Although the purpose
of this policy was to control the increasing drug expenditure in
China, it failed to do so, as shown in our results. Our results were
consistent with other researches’ finding that the decrease in
drug price had a very limited effect on the controlling of
pharmaceutical expenditure [4–6]. Furthermore, the policy drove
many cheap drugs out of the pharmaceutical market and most of
them were necessary drugs for certain diseases [20–22].0.6
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ig. 3 – Three determinants indices analysis for oral anti-
nfective drugs from 2003 to 2007.
Table 3 – Six determinants of the increasing anti-
infective injections expenditures from 2006
to 2007.
Decomposition factors Anti-infective
injections
expenditure
increasing
Expenditures changes 1.26
Price effect 0.94
Drug price 0.93
Generic name substitution 1.01
Quantity effect 1.15
Annual inpatient times 1.07
Size of prescriptions per inpatient 1.07
Therapeutic effect 1.17
Therapeutic substitution 1.07
Drug substitution 1.09
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over cheap ones in China had a more important influence on the
increasing drug price than it did in other countries [12,15,23].
That is, physicians tend to prescribe expensive drugs. In China,
hospitals have a fixed 15% add-up between wholesale price and
retail price by policy [24]. Thus, hospitals can obtain more
revenue by ‘‘selling’’ expensive drugs than cheap ones. Such a
price regulation gives hospitals incentives for underproviding
lower price drugs and overproviding higher price drugs. Above
distorted pricing systems give perverse incentives, helping to
escalate the expenditure.
We found that injections substituted oral forms and contrib-
uted more to pharmaceutical expenditure. Part of the reason is
that on average the price of injections is higher than that of the
corresponding oral ones. The results are in accordance with the
fact that Chinese people had infusion treatment 8 times on
average in 2009, which is 2.5 to 3.6 times higher than the world
average [25].
Besides many factors that contribute to the increasing quan-
tity of drugs, such as aging population, expending insurance
coverage, and updating health technology, physicians may be
prescribing more drugs than the patients’ need in China. Chinese
public hospitals are the main health services providers. But they
cannot get adequate financial support from the government and
most of the health services are below cost, and so they have to
make profit on drugs to run the hospital. This gives physicians
incentives for overproviding drugs to patients. This situation is
even worse than the one that stimulates to use unnecessary
drugs without strict regulations of clinical practice guidelines on
drug prescriptions [24]. The same phenomenon happened
according to World Health Organization’s statistics, which
revealed that as high as 80% of all patients received antibiotic
drugs in Chinese hospitals compared with the international
average of 30% [26]. Prescribing unnecessary anti-infective drugs
made China the country with the most rapid growth rate of
bacterial resistance in the world [27]. The serious problem of
inappropriate prescribing of anti-infective drugs induces antimi-
crobial resistance, which has sparked public panic and fear on
global public health [28,29].
Our results also showed that generic substitution increased
the pharmaceutical expenditure. This result was not consistent
with what was reported in international literature, which had a
negative effect on expenditure [30,31]. We found that there was a
huge price difference among drugs from different producers; the
largest price difference is 27-fold in our data set, which lies
between brand name drug and the lowest generics. In China all
drugs, as long as their generic names are in the reimbursementformulary, can be reimbursed whatever their price. Therefore,
physicians prefer expensive ones; that is, cost-effective generics
are substituted by expensive equivalents [32]. Therefore, we did
not observe the generic substitution effect in China as what
happened in other countries.
The discussion indicated that systemic interventions in phar-
maceutical policies are needed to change the current prescribing
pattern among Chinese physicians, and they should be closely
integrated into broader health policies, not only drug policies.
This research, however, has three limitations. First, our
results cannot represent all drugs in the program, because in
2004 the Ministry of Human Resource and Social Security of
China added new drugs to the reimbursement pharmaceutical
formulary and our basic analysis for years 2003 to 2007 did not
include these drugs. So, we may underestimate the quantity
effects and the therapeutic choices and overestimate price
effects, because newly added drug price are much higher. Second,
the claims data in the UEBMI system in Tianjin, like most
automatically generated database, lack information on medica-
tion outside the program. Third, although the UEBMI system
covers the most important population in terms of drug utiliza-
tion, we must be cautious in applying the results from the UEBMI
system to the total population in Tianjin, China.Acknowledgment
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